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LEllERS TO THE EDITORS 
In Vivo Selection of Streptococcus pneumoniae, 
Resistant to Quinolones, Including Sparfloxin 
Louis Bernard‘, Jean-Claude Nguyen ?An2 andlean-Luc Mainardi’ 
Pneumococcal infections are an important cause of 
morbidity and mortality. The development of resistance 
to p-lactams has restricted the choice of antibiotics 
for therapy (1). Pneumococcal strains are often resistant 
to other antibiotics, emphasizing the need for new 
effective compounds. New fluoroquinolones such 
as sparfloxacin, the most active quinolone against 
Streptococcus pneumoniae (MICgo= 0.5 p,g/ml) (2), are 
considered as alternatives for the treatment of res- 
piratory infections. However, 0.5% of S. pneumoniae in 
France are resistant to sparfloxacin ( M I 0 4  pg/ml) 
and other fluoroquinolones (3, 4). The selection of 
S. pneumoniae resistant to quinolones has also been 
demonstrated in vitro (5). We report herein the in vivo 
selection of a strain of S. pneumoniae resistant to fluoro- 
quinolones, including sparfloxacin. 
In November 1994, a 31-year-old HIV-infected 
patient, allergic to penicillin, was hospitalized for the 
treatment of a bronchitis and a maxillary sinusitis due 
to Haemophilus injuenzae and S. pneumoniae serotype 
14, resistant to macrolides and co-trimoxazole but 
susceptible to penicillin (MIC = 0.015 pg/ml), tetra- 
cycline and chloramphenicol. The MICs of pefloxacin, 
ofloxacin, ciprofloxacin and sparfloxacin were 32, 4, 
4 and 0.5 pg/ml respectively. Pefloxacin (400 mg 
bid i.v.) was administered empirically for 48 h, with- 
out improvement, and replaced by ofloxacin (200 mg 
bid orally) for 10 days. Clinical recovery was obtained. 
Ten days after the last administration of ofloxacin, 
a therapeutic regimen including clarithromycin, 
lamprene, myambutol and ciprofloxacin (500 mg tid) 
was started because one blood culture was positive with 
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Mycobacterium avium. At the same time, S. pneumoniae 
was isolated from the sputum. The strain had the 
same pulsotype in pulse field gel electrophoresis and 
the same serotype 14 as the previous one and showed 
the same pattern of antibiotic resistance except for the 
quinolones. MICs were now: pefloxacin >128 p,g/ml, 
ofloxacin 32 p,g/ml, ciprofloxacin 32 pg/ml and spar- 
floxacin 16 pg/ml. Treatment was postponed because 
the patient had no clinical symptoms. One week 
later, he was rehospitalized for a bilateral pneumonia, 
with positive blood culture for the same strain of 
S. pneumoniae. Recovery was obtained with the 
administration of teicoplanin (400 mg bid i.m. for 48 h 
and then 400 mg daily for 10 days). The original isolate 
probably had a dissociated low-level resistance to the 
quinolones, undetectable by the usual methods. 
In conclusion, the first treatment with ofloxacin 
was clinically successhl; a high dose of ciprofloxacin 
was given subsequently for a Mycobacterium avium 
infection, and a variant highly resistant to the quino- 
lones was selected and became responsible for a severe 
relapse. Our  comments are in fact questions: “How 
should we interpret a dissociated susceptibility to 
fluoroquinolones?”. Was the higher MIC to pefloxacin 
an indication of low-level resistance to other agents? 
Would the use of sparfloxacin as initial therapy have 
been justified and prevented the emergence of the 
resistant variant? 
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Reply by Professor Richard Wise 
The authors pose a number of interesting questions 
which revolve round the observation that, apparently, a 
relatively greater degree of insusceptibility can occur to 
one or more quinolones in comparison with others. 
What is the clinical significance of this observation? 
The increases in the MICs between the two 
isolations of S. pneurnoniae were >%fold for pefloxacin, 
%fold for ofloxacin and ciprofloxacin and 32-fold for 
sparfloxacin. The original isolate must be considered to 
be more resistant to all these agents than the majority 
of strains, as the MIC90 values reported are 8->16 
p g / d  of pefloxacin, 1-2 p g / d  of ofloxacin and 
ciprofloxacin (l), and 0.25-0.5 p g / d  of sparfloxacin 
(2). Hence the questions to answer are: what were the 
mechanisms of resistance in the original isolate and in 
the later isolate, and why was the susceptibility to 
sparfloxacin more affected than that to the other 
quinolones? 
Alterations to DNA gyrase in gram-positive and 
gram-negative bacteria is usually associated with a 4- 
to 32-fold increase in MIC of ciprofloxacin (3) and 
a parallel increase is seen for other quinolones. 
Alterations to the inner membrane in gram-positive 
bacteria can occur. In Staphylococcus aureus the norA 
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gene can alter drug efRux mechanisms, and this can 
differentially affect the various quinolones (3). Indirect 
evidence from our own investigations suggests that 
sparfloxacin has an enhanced capacity to pass certain 
mammalian membranes, and therefore, possibly bacterial 
membranes. Hence the possession of both a norA gene 
and a gyrA mutation might well be expected to affect 
susceptibility to sparfloxacin more than to other quino- 
lones. However, this suggestion is just speculation and 
requires confirmation. 
To answer the other points . . . to use the most 
active quinolone (sparfloxacin) at full dosage would 
certainly seem to carry the greatest likelihood of a 
successful outcome. Ofloxacin was used at a rather low 
dose in this case, in my opinion. The problem ofwhich 
quinolone to use to test the susceptibility to the class 
of quinolones is a thorny issue. The Working Party 
of the British Society for Antimicrobial Chemo- 
therapy (4) suggested that the least active member of a 
group of similar agents should be chosen to represent 
the group, because “false sensitivity” rather than “false 
resistance” is the lesser of two evils in susceptibility 
reporting. 
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